Does the media prefer BBIO or AMLX?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat BridgeBio Pharma's score of 0.90 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMLX or EXEL?

In the previous week, Exelixis had 21 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 27 mentions for Exelixis and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Exelixis' score of 0.54 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AMLX or SMMT?

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amylyx Pharmaceuticals N/A N/A -$144.74M -$1.43 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is AMLX or SMMT more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -52.92% -48.53% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor AMLX or SMMT?

In the previous week, Summit Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for Summit Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Summit Therapeutics' score of 1.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMLX or BMRN?

In the previous week, BioMarin Pharmaceutical had 15 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat BioMarin Pharmaceutical's score of 0.79 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or AMLX?

In the previous week, Halozyme Therapeutics had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Halozyme Therapeutics' score of 1.02 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$31.62 -0.47 (-1.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$31.62 0.00 (0.00%)

As of 09/11/2026 07:51 PM Eastern

Compare

AMLX vs. BBIO, EXEL, SMMT, BMRN, and HALO

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? Amylyx Pharmaceuticals's main competitors and comparable companies include BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat BridgeBio Pharma's score of 0.90 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma currently has a consensus target price of $102.61, suggesting a potential upside of 41.65%. Amylyx Pharmaceuticals has a consensus target price of $36.50, suggesting a potential upside of 15.43%. Given BridgeBio Pharma's higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Amylyx Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A

Summary

BridgeBio Pharma beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Exelixis?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Amylyx Pharmaceuticals currently has a consensus price target of $36.50, suggesting a potential upside of 15.43%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 10.79%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Amylyx Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38

In the previous week, Exelixis had 21 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 27 mentions for Exelixis and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Exelixis' score of 0.54 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Exelixis has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65

Exelixis has a net margin of 35.33% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Exelixis	35.33%	42.17%	31.76%

Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Summary

Exelixis beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Summit Therapeutics	N/A	-168.94%	-141.92%

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Amylyx Pharmaceuticals has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

In the previous week, Summit Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 9 mentions for Summit Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Summit Therapeutics' score of 1.19 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Amylyx Pharmaceuticals currently has a consensus price target of $36.50, indicating a potential upside of 15.43%. Summit Therapeutics has a consensus price target of $25.91, indicating a potential upside of 47.63%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

Summary

Amylyx Pharmaceuticals beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Amylyx Pharmaceuticals' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Amylyx Pharmaceuticals presently has a consensus target price of $36.50, suggesting a potential upside of 15.43%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 35.77%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

BioMarin Pharmaceutical has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51

In the previous week, BioMarin Pharmaceutical had 15 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat BioMarin Pharmaceutical's score of 0.79 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	8 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Summary

BioMarin Pharmaceutical beats Amylyx Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 14.93%. Amylyx Pharmaceuticals has a consensus price target of $36.50, indicating a potential upside of 15.43%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.71	$316.89M	$3.35	32.00
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A

Halozyme Therapeutics has a net margin of 24.86% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

In the previous week, Halozyme Therapeutics had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Halozyme Therapeutics' score of 1.02 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Amylyx Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.52B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-22.11	14.25	275.24	25.29
Price / Sales	N/A	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	11.37	15.12	10.33	6.20
Net Income	-$144.74M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.27%	-4.34%	-3.32%	-2.35%
1 Month Performance	35.42%	-0.02%	-0.41%	-2.77%
1 Year Performance	171.42%	40.64%	19.21%	7.63%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	3.949 of 5 stars	$31.62 -1.5%	$36.50 +15.4%	+167.1%	$3.52B	N/A	N/A	136	Positive News
BBIO BridgeBio Pharma	3.4571 of 5 stars	$74.84 flat	$101.53 +35.7%	+37.7%	$14.63B	$502.08M	N/A	400	Analyst Forecast
EXEL Exelixis	2.4691 of 5 stars	$59.01 flat	$50.07 -15.2%	+43.6%	$14.62B	$2.32B	18.56	1,077	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.6754 of 5 stars	$17.60 flat	$24.07 +36.8%	-5.6%	$14.04B	N/A	N/A	110	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6227 of 5 stars	$66.53 flat	$89.17 +34.0%	+17.5%	$12.88B	$3.22B	179.81	3,221	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amylyx Pharmaceuticals compare to Exelixis?

Summary

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Summary

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. BBIO, EXEL, SMMT, BMRN, and HALO

How does Amylyx Pharmaceuticals compare to BridgeBio Pharma?

Is BBIO or AMLX more profitable?

Which has more risk and volatility, BBIO or AMLX?

Do institutionals and insiders hold more shares of BBIO or AMLX?

Does the media prefer BBIO or AMLX?

Do analysts prefer BBIO or AMLX?

Which has better valuation & earnings, BBIO or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Exelixis?

Do analysts rate AMLX or EXEL?

Does the media refer more to AMLX or EXEL?

Do insiders and institutionals believe in AMLX or EXEL?

Which has preferable valuation & earnings, AMLX or EXEL?

Is AMLX or EXEL more profitable?

Which has more volatility & risk, AMLX or EXEL?

Summary

How does Amylyx Pharmaceuticals compare to Summit Therapeutics?

Is AMLX or SMMT more profitable?

Which has preferable earnings & valuation, AMLX or SMMT?

Which has more risk & volatility, AMLX or SMMT?

Does the media favor AMLX or SMMT?

Do insiders & institutionals have more ownership in AMLX or SMMT?

Do analysts rate AMLX or SMMT?

Summary

How does Amylyx Pharmaceuticals compare to BioMarin Pharmaceutical?

Do insiders & institutionals hold more shares of AMLX or BMRN?

Is AMLX or BMRN more profitable?

Do analysts prefer AMLX or BMRN?

Which has stronger earnings and valuation, AMLX or BMRN?

Does the media favor AMLX or BMRN?

Which has more volatility & risk, AMLX or BMRN?

Summary

How does Amylyx Pharmaceuticals compare to Halozyme Therapeutics?

Do analysts rate HALO or AMLX?

Do insiders and institutionals have more ownership in HALO or AMLX?

Which has higher earnings and valuation, HALO or AMLX?

Is HALO or AMLX more profitable?

Does the media prefer HALO or AMLX?

Which has more volatility & risk, HALO or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools